INTRODUCE
Wuhan COBOT Technology Co., Ltd.As a representative enterprise in the medical robot industry, Wuhan Cobot Technology Co., Ltd. focuses on the R&D and manufacturing of physical products and operating systems for intelligent medical robots, with core development priorities including ultrasound robots and smart pharmacy robots.
COBOT has more than 200 employees, 50% of whom work in R&D. Its expert advisory team includes academicians of the Chinese Academy of Sciences and recipients of the National Science Fund for Distinguished Young Scholars. Its core technical backbone consists of over 10 high-level talents, including awardees of the Hubei Top Young Talents Program, Hubei Top Young Medical Talents Program, and the "3551" Optics Valley Innovative Talent Program.
Since its establishment, Cobot has successively won honors such as the national-level specialized, sophisticated, distinctive and novel "Little Giant" enterprise, National High-Tech Enterprise, Benchmark Enterprise in the Smart Medical Industry of China's Software and Information Service Industry, and Hubei Provincial Listed Reserve Golden Seed Enterprise. It has received 6 rounds of financing from Matrix Partners China, central government funds, Wuhan High-tech, etc., with the amount reaching nearly hundreds of millions of yuan.
The company has an intelligent manufacturing base of over 10,000 square meters, equipped with production equipment such as CNC machining centers and laser cutting machines. It has a complete management system and technical personnel of various types of work, which can meet the needs of future market expansion.
0
%
Proportion of R&D personnel
0
+
Invention Patent
0
+
Honor & Qualiflcation
0
+
Provincial Major Special Projects
VISION
VALUES
INNOVATION
SERVICE

HISTORY
2016
Closed Series B financing co-led by Matrix China Partners, GGV Capital, and Blueprint Ventures.
2018
Small-Batch Commercialization Achieved for Product Line.
2020
Implemented nationwide application deployment, establishing a designated demonstration model in the niche sector.Spearheaded development of Smart Pharmacy Construction and Accreditation Standards Critical Nuances.
2022
The intelligent ultrasound robot has been granted NMPA Class III Medical Device Registration Certificate.
2024
Selected as a National Key "Specialized, Sophisticated, Distinctive and Innovative" Little Giant Enterprise. Commissioned a 10,000-square-meter GMP-compliant Intelligent Manufacturing Facility.
Company Establishment
Completed Angel Round financing led by Empower Investment. Closed Series A financing led by Matrix Partners China.
2017
Official Release of Commercial Edition: Intelligent Robotics Operating System.
2019
Series B Extension financing from AlphaX Partners to accelerate market expansion.
2021
Closed Series C round with RMB 100M+ investment from China Create Capital. Engineering Validation Completed for Ultrasound-Guided Surgical Robot Prototype.
2023
Conferred the National-Level "Specialized, Sophisticated, Distinctive and Innovative" Little Giant Enterprise Honor. Secured over RMB 100 million funding from Wuhan Hi-Tech Holding and Xiantao Hi-Tech Industrial Investment.
2025
HONOR & QUALIFLCATION
TECHNOLOGY&STRENGTH
It has successfully broken through key technologies such as visual-force multi-modal intelligent perception, real-time robot motion planning, and robot complex operation motion control, and has developed the domestically pioneered "Tianji" ultrasonic embodied intelligent robot. It has undertaken and participated in 16 major scientific research projects including national key R&D programs, Hubei Provincial major projects of technological innovation special funds, and Wuhan Municipal Science and Technology Programs. It has applied for 417 intellectual property rights, among which more than 150 are invention patents.